<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HDEFAEE7ACA7C4CD9A3DA9E9787E77EF8" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 5686 IH: Medicare Clear Health Options in Care for Enrollees Act of 2018</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2018-05-07</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 5686</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20180507">May 7, 2018</action-date><action-desc><sponsor name-id="P000594">Mr. Paulsen</sponsor> (for himself, <cosponsor name-id="K000188">Mr. Kind</cosponsor>, <cosponsor name-id="C001092">Mr. Collins of New York</cosponsor>, and <cosponsor name-id="L000588">Mr. Lamb</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XVIII of the Social Security Act to require prescription drug plans under Medicare
			 part D to include information on the adverse effects of opioid
			 overutilization and of coverage of nonpharmacological therapies and
			 nonopioid medications or devices used to treat pain.</official-title></form>
	<legis-body id="H8F27B1C6DE194A13AF8B06AB33E534FB" style="OLC">
 <section id="HBEA1647FCBED4B0584B2E43EA3ADD602" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Medicare Clear Health Options in Care for Enrollees Act of 2018</short-title></quote> or the <quote><short-title>Medicare CHOICE Act of 2018</short-title></quote>.</text> </section><section id="H2DB701378051467A9FD0517B5D95DFED" section-type="subsequent-section"><enum>2.</enum><header>Requiring Medicare part D prescription drug plans to include information on adverse effects relating to opioids and coverage of nonpharmacological therapies and nonopioid medications or devices used to treat pain</header><text display-inline="no-display-inline">Section 1860D–4(a)(1) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-104">42 U.S.C. 1395w–104(a)(1)</external-xref>) is amended—</text>
 <paragraph id="HAB37C055AE4643C4814A1A8D5660F069"><enum>(1)</enum><text>in subparagraph (A), by inserting <quote>, subject to subparagraph (C),</quote> before <quote>including</quote>;</text> </paragraph><paragraph id="H82A4E51760A64B7F8CE5208C06C5F96D"><enum>(2)</enum><text>in subparagraph (B), by adding at the end the following new clause:</text>
				<quoted-block display-inline="no-display-inline" id="H0233963FA2134725A2929344BA9C9203" style="OLC">
 <clause id="H76FF9E89CB684B2B95E43B5A669BDDBB"><enum>(vi)</enum><text display-inline="yes-display-inline">For plan year 2021 and each subsequent plan year, subject to subparagraph (C), with respect to the treatment of pain—</text>
 <subclause id="H756F65C7C2F740C9A219D29DFE4100C7"><enum>(I)</enum><text>the adverse effects of prolonged opioid use; and</text> </subclause><subclause id="HF3DC40EA993547D6BA7C9559F790DAAA"><enum>(II)</enum><text>coverage of nonpharmacological therapies, devices, and nonopioid medications—</text>
 <item id="H360611CF9F574E22A4D58AA8912F92CC"><enum>(aa)</enum><text>in the case of an MA-PD plan under part C, under such plan; and</text> </item><item id="HA4F851BC913949069C1DCD5C84D5413E"><enum>(bb)</enum><text>in the case of a prescription drug plan under such plan and under parts A and B.</text></item></subclause></clause><after-quoted-block>; and</after-quoted-block></quoted-block>
 </paragraph><paragraph id="HD3E8273469FF4F67AAC369268B3DB7DB"><enum>(3)</enum><text>by adding at the end the following new subparagraph:</text> <quoted-block display-inline="no-display-inline" id="H88806039A3E2446896E07DE720962EA4" style="OLC"> <subparagraph id="HA18ACA78BCDD4EF9BC3C6906CBF921C1"><enum>(C)</enum><header>Targeted provision of information</header><text display-inline="yes-display-inline">A PDP sponsor of a prescription drug plan may, in lieu of disclosing the information described in subparagraph (B)(vi) to each enrollee under the plan, disclose such information through mail or electronic communications to a subset of enrollees under the plan, such as enrollees who have been prescribed an opioid in the previous two-year period.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
			</paragraph></section></legis-body></bill>


